IL308836A - Lipid Particles Containing Baboon Truncated Endogenous Retrovirus (BAEV) Envelope Glycoprotein and Related Methods and Uses - Google Patents
Lipid Particles Containing Baboon Truncated Endogenous Retrovirus (BAEV) Envelope Glycoprotein and Related Methods and UsesInfo
- Publication number
- IL308836A IL308836A IL308836A IL30883623A IL308836A IL 308836 A IL308836 A IL 308836A IL 308836 A IL308836 A IL 308836A IL 30883623 A IL30883623 A IL 30883623A IL 308836 A IL308836 A IL 308836A
- Authority
- IL
- Israel
- Prior art keywords
- baev
- truncated
- particles containing
- related methods
- lipid particles
- Prior art date
Links
- 101710121417 Envelope glycoprotein Proteins 0.000 title 1
- 241001504519 Papio ursinus Species 0.000 title 1
- 102100021696 Syncytin-1 Human genes 0.000 title 1
- 150000002632 lipids Chemical class 0.000 title 1
- 239000002245 particle Substances 0.000 title 1
- 241001430294 unidentified retrovirus Species 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163194880P | 2021-05-28 | 2021-05-28 | |
| PCT/US2022/031459 WO2022251712A1 (en) | 2021-05-28 | 2022-05-27 | Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL308836A true IL308836A (en) | 2024-01-01 |
Family
ID=82851603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL308836A IL308836A (en) | 2021-05-28 | 2022-05-27 | Lipid Particles Containing Baboon Truncated Endogenous Retrovirus (BAEV) Envelope Glycoprotein and Related Methods and Uses |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240254168A1 (https=) |
| EP (1) | EP4347620A1 (https=) |
| JP (1) | JP2024521811A (https=) |
| CN (1) | CN117642420A (https=) |
| AU (1) | AU2022280957A1 (https=) |
| CA (1) | CA3219487A1 (https=) |
| IL (1) | IL308836A (https=) |
| WO (1) | WO2022251712A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020252455A1 (en) | 2019-06-13 | 2020-12-17 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| CA3189601A1 (en) | 2020-07-24 | 2022-01-27 | The General Hospital Corporation | Enhanced virus-like particles and methods of use thereof for delivery to cells |
| CN113608287B (zh) * | 2021-08-06 | 2023-06-02 | 暨南大学 | 一种微透镜及其应用 |
| EP4463135A2 (en) * | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2024081820A1 (en) * | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| EP4724461A1 (en) * | 2023-06-07 | 2026-04-15 | The Broad Institute, Inc. | Engineered viral like particles (evlps) for the selective transduction of target cells |
| WO2024259051A1 (en) * | 2023-06-14 | 2024-12-19 | The Children's Medical Center Corporation | Systems and methods for modifying a polynucleotide |
| CN119264228B (zh) * | 2023-07-04 | 2025-11-25 | 清华大学 | 一种具有广泛细胞嗜性和高效感染效率的包膜蛋白及其应用 |
| TW202540399A (zh) * | 2023-11-14 | 2025-10-16 | 中央研究院 | 用於有效包裹病毒顆粒之經修改的細胞株 |
| CN119020418B (zh) * | 2024-08-17 | 2025-06-13 | 广东君厚生物医药有限公司 | BaEV逆转录病毒载体的包装方法及其包装细胞系 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| GB9526131D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Recombinant chimeric receptors |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| PT904392E (pt) | 1996-10-17 | 2001-06-29 | Oxford Biomedica Ltd | Vectores retrovirais |
| GB9720465D0 (en) | 1997-09-25 | 1997-11-26 | Oxford Biomedica Ltd | Dual-virus vectors |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| ES2373406T3 (es) | 1997-12-22 | 2012-02-03 | Oxford Biomedica (Uk) Limited | Vectores basados en el virus de la anemia infecciosa equina (vaie). |
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
| GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
| US9085778B2 (en) | 2006-05-03 | 2015-07-21 | VL27, Inc. | Exosome transfer of nucleic acids to cells |
| EP2498823B1 (en) | 2009-11-13 | 2018-08-29 | INSERM - Institut National de la Santé et de la Recherche Médicale | Direct protein delivery with engineered microvesicles |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CN103946952A (zh) | 2011-09-16 | 2014-07-23 | 宾夕法尼亚大学董事会 | 用于治疗癌症的rna改造的t细胞 |
| ES2642276T3 (es) * | 2011-09-29 | 2017-11-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Vectores lentivirales pseudotipados con glicoproteínas de envoltura BaEV mutantes |
| EP2844746A4 (en) | 2012-03-26 | 2016-07-20 | Univ California | PSEUDOTYPIZED LENTIVIRES WITH NIPAH VIRUS COVERS AND METHOD OF USE THEREOF |
| CN105051192B (zh) | 2012-11-13 | 2020-04-17 | 科迪艾克生物科学公司 | 治疗剂的递送 |
| EP2990416B1 (en) | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| WO2016077639A2 (en) | 2014-11-12 | 2016-05-19 | VL27, Inc. | Nanovesicular therapies |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| US11623950B2 (en) * | 2015-07-09 | 2023-04-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Lentiviral vector expressing membrane-anchored or secreted antibody |
| US20180291080A1 (en) | 2015-09-28 | 2018-10-11 | Trustees Of Dartmouth College | Chimeric antigen receptor, regulatory cells and methods of use |
| JP2018534264A (ja) | 2015-09-28 | 2018-11-22 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 自己免疫および同種免疫への治療的介入としてのキメラ抗原受容体（ｃａｒ）ｔ細胞 |
| WO2017068077A1 (en) | 2015-10-20 | 2017-04-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods and products for genetic engineering |
| US11903974B2 (en) | 2015-11-30 | 2024-02-20 | Flagship Pioneering Innovations V, Inc. | Methods and compositions relating to chondrisomes from cultured cells |
| CA3017586A1 (en) | 2016-03-15 | 2017-09-21 | Codiak Biosciences, Inc. | Therapeutic membrane vesicles |
| EP3235908A1 (en) | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
| CA3062426A1 (en) | 2017-05-08 | 2018-11-15 | Flagship Pioneering Innovations V, Inc. | Compositions for facilitating membrane fusion and uses thereof |
| KR102761791B1 (ko) | 2017-06-26 | 2025-02-05 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적화된 핵산 편집을 위한 crispr/cas-아데닌 데아미나아제 기반 조성물, 시스템 및 방법 |
| WO2019005886A1 (en) | 2017-06-26 | 2019-01-03 | The Broad Institute, Inc. | CRISPR / CAS-CYTIDINE DEAMINASE COMPOSITIONS, SYSTEMS AND METHODS FOR TARGETED EDITING OF NUCLEIC ACIDS |
| US20210187018A1 (en) | 2017-12-07 | 2021-06-24 | Flagship Pioneering Innovations V, Inc. | Cytobiologics and therapeutic uses thereof |
| WO2019126709A1 (en) | 2017-12-22 | 2019-06-27 | The Broad Institute, Inc. | Cas12b systems, methods, and compositions for targeted dna base editing |
| EP3728576A4 (en) | 2017-12-22 | 2021-11-24 | The Broad Institute, Inc. | CAS12B SYSTEMS, METHODS AND COMPOSITIONS FOR SPECIFIC EDITING OF RNA BASES |
| US20210079366A1 (en) | 2017-12-22 | 2021-03-18 | The Broad Institute, Inc. | Cas12a systems, methods, and compositions for targeted rna base editing |
| WO2019157319A1 (en) | 2018-02-12 | 2019-08-15 | Flagship Pioneering Innovations V, Inc. | Devices and methods for delivering material into a biological tissue or cell |
| AU2019222560B2 (en) | 2018-02-17 | 2025-07-03 | Flagship Pioneering Innovations V, Inc. | Compositions and methods for membrane protein delivery |
| SG11202011015QA (en) | 2018-05-15 | 2020-12-30 | Flagship Pioneering Innovations V Inc | Fusosome compositions and uses thereof |
| CN112955174A (zh) | 2018-07-09 | 2021-06-11 | 旗舰先锋创新V股份有限公司 | 融合剂脂质体组合物和其用途 |
| WO2020051562A2 (en) | 2018-09-07 | 2020-03-12 | Beam Therapeutics Inc. | Compositions and methods for improving base editing |
| AU2019378883A1 (en) | 2018-11-14 | 2021-06-03 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for T cell delivery |
| US20220008557A1 (en) | 2018-11-14 | 2022-01-13 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for cns delivery |
| CN113631718A (zh) | 2018-11-14 | 2021-11-09 | 旗舰先锋创新V股份有限公司 | 用于特定隔室货物递送的组合物和方法 |
| EP3880832A1 (en) | 2018-11-14 | 2021-09-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for hematopoietic stem cell delivery |
| WO2020181195A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | T:a to a:t base editing through adenine excision |
| WO2020181202A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | A:t to t:a base editing through adenine deamination and oxidation |
| WO2020181178A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | T:a to a:t base editing through thymine alkylation |
| WO2020181193A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | T:a to a:t base editing through adenosine methylation |
| WO2020191233A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| EP4100519A2 (en) | 2020-02-05 | 2022-12-14 | The Broad Institute, Inc. | Adenine base editors and uses thereof |
| IL297761A (en) | 2020-05-08 | 2022-12-01 | Broad Inst Inc | Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence |
| CA3193099A1 (en) | 2020-09-24 | 2022-03-31 | David R. Liu | Prime editing guide rnas, compositions thereof, and methods of using the same |
-
2022
- 2022-05-27 JP JP2023573116A patent/JP2024521811A/ja active Pending
- 2022-05-27 WO PCT/US2022/031459 patent/WO2022251712A1/en not_active Ceased
- 2022-05-27 CN CN202280050044.8A patent/CN117642420A/zh active Pending
- 2022-05-27 CA CA3219487A patent/CA3219487A1/en active Pending
- 2022-05-27 US US18/563,812 patent/US20240254168A1/en active Pending
- 2022-05-27 AU AU2022280957A patent/AU2022280957A1/en active Pending
- 2022-05-27 EP EP22754193.5A patent/EP4347620A1/en active Pending
- 2022-05-27 IL IL308836A patent/IL308836A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022251712A1 (en) | 2022-12-01 |
| JP2024521811A (ja) | 2024-06-04 |
| CA3219487A1 (en) | 2022-12-01 |
| US20240254168A1 (en) | 2024-08-01 |
| AU2022280957A1 (en) | 2023-11-30 |
| CN117642420A (zh) | 2024-03-01 |
| EP4347620A1 (en) | 2024-04-10 |
| AU2022280957A9 (en) | 2023-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL308836A (en) | Lipid Particles Containing Baboon Truncated Endogenous Retrovirus (BAEV) Envelope Glycoprotein and Related Methods and Uses | |
| ZA202003770B (en) | Mhc class i associated peptides for prevention and treatment of multiple flavi virus | |
| MX2016014187A (es) | Adenovirus que comprende una fraccion de union a albumina. | |
| MX2018009312A (es) | Celulas presentadoras de antigeno modificadas por ingenieria y usos de las mismas. | |
| MA44059B1 (fr) | Antigènes du virus de l'immunodéficience humaine, vecteurs, compositions, et leurs procédés d'utilisation | |
| IL158963A0 (en) | Dental restorative materials | |
| WO2020033527A3 (en) | Recombinant biologically contained filovirus vaccine | |
| MA56468A (fr) | Protéines de liaison à l'antigène de carcinome 1 à cellules squameuses de l'oesophage anti-new york (ny-eso-1) et leurs procédés d'utilisation | |
| EA202192860A1 (ru) | Сиалилированные гликопротеины | |
| Chauhan et al. | Effect of different intracoronal bleaching methods on shear bond strength of ceramic brackets bonded to bleached enamel: An: in-vitro: study | |
| WO2019058133A3 (en) | MHC CLASS I ASSOCIATED PEPTIDES FOR THE PREVENTION AND TREATMENT OF ZIKA VIRUS | |
| EP4190848A4 (en) | Surface-functionalized material and modified material, and preparation methods therefor and use thereof | |
| EP2632942A4 (en) | RECOMBINANT ENVELOPE PROTEIN OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND VACCINE CONTAINING THE SAME | |
| Rimmelzwaan et al. | Human airway epithelial cells present antigen to influenza virus-specific CD8+ CTL inefficiently after incubation with viral protein together with ISCOMATRIX® | |
| MY142996A (en) | Intranasal influenza vaccine based on virosomes | |
| US9668709B2 (en) | Barrier envelope for an imaging plate | |
| Jabbarifar et al. | In vitro comparison of microleakage of a self-etching fissure sealant with a flowable composite resin and a conventional fissure sealant | |
| FR3074820B1 (fr) | Module de construction pour mur, plancher ou plafond et machine de remplissage pour celui-ci | |
| JP5180586B2 (ja) | 指輪及び指輪の製造方法 | |
| MY200111A (en) | Composition of subunit dengue vaccine | |
| EP2235065A4 (en) | Glycoprotein oligomer of the HIV-1 envelope and its methods of use | |
| US1094289A (en) | Moisture-proof box. | |
| Piaggio et al. | Is there evidence for tripling the dose of 200 mg mifepristone for medical abortion? | |
| Steppa et al. | Exploring the population of Galactic very-high-energy $\gamma $-ray sources | |
| RU143264U1 (ru) | Упаковка для почтового отправления |